TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has entered into a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner for the pharma, biotech, and nutrition industries. The agreement aims to increase access to CleanCap mRNA capping technologies in response to the growing demand for mRNA.
Under the terms of the agreement, TriLink will supply Lonza with its patented CleanCap M6, CleanCap AG 3’OMe, CleanCap AG, and CleanCap AU cap analogs for use in Lonza’s global mRNA development and manufacturing services, spanning from pre-clinical to Phase III programs.
The CleanCap technology offered by TriLink is known for its high efficiency capping process, with over 95% capping efficiency, which simplifies the mRNA production process when compared to traditional capping methods.
Drew Burch, President of Nucleic Acid Production at TriLink, expressed excitement about providing their innovative capping solutions to Lonza and its clients. He highlighted how CleanCap technology has been instrumental in speeding up programs from discovery to clinical trials by enhancing mRNA function, streamlining manufacturing processes, and increasing capped material yield.
TriLink’s CleanCap capping technology has been utilized in a majority of approved mRNA and saRNA vaccines since it was introduced in 2017. In May 2023, TriLink introduced its most robust CleanCap analog to date, CleanCap M6, which has shown to increase mRNA expression by more than 30% compared to enzymatic capping methods.